Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Liabilities and Shareholders Equity: 2022-2025

Historic Liabilities and Shareholders Equity for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Sep 2025 value amounting to $513.8 million.

  • Day One Biopharmaceuticals' Liabilities and Shareholders Equity fell 14.49% to $513.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 billion, marking a year-over-year increase of 26.18%. This contributed to the annual value of $582.8 million for FY2024, which is 54.98% up from last year.
  • According to the latest figures from Q3 2025, Day One Biopharmaceuticals' Liabilities and Shareholders Equity is $513.8 million, which was down 1.01% from $519.0 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' 5-year Liabilities and Shareholders Equity high stood at $600.8 million for Q3 2024, and its period low was $267.8 million during Q1 2022.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $450.8 million (2023), whereas its average is $458.4 million.
  • Examining YoY changes over the last 5 years, Day One Biopharmaceuticals' Liabilities and Shareholders Equity showed a top increase of 63.59% in 2025 and a maximum decrease of 14.49% in 2025.
  • Over the past 4 years, Day One Biopharmaceuticals' Liabilities and Shareholders Equity (Quarterly) stood at $349.1 million in 2022, then rose by 7.73% to $376.0 million in 2023, then skyrocketed by 54.98% to $582.8 million in 2024, then declined by 14.49% to $513.8 million in 2025.
  • Its last three reported values are $513.8 million in Q3 2025, $519.0 million for Q2 2025, and $534.4 million during Q1 2025.